Gout Therapeutics Market Explained: What Is Fueling Growth To $5.6 Billion By 2030?

Gout Therapeutics Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Gout Therapeutics Market Forecast: What Value Will The Market Reach By 2030?

The market for gout therapeutics has experienced substantial expansion recently. This market is projected to expand from $3.22 billion in 2025 to $3.59 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 11.6%. Factors contributing to its historical growth include shifts in dietary lifestyles, the widespread availability of NSAIDs, a rise in arthritis diagnoses, the provision of hospital rheumatology services, and advancements in pain management drug development.

The market for gout therapeutics is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach a valuation of $5.6 billion, demonstrating a compound annual growth rate (CAGR) of 11.8%. Factors contributing to this growth during the projected period include an increasing aging population, the escalating burden of chronic diseases, advancements in preventive arthritis care, enhanced patient compliance tools, and the adoption of personalized treatment approaches. Key trends anticipated during the forecast period encompass a rising incidence of lifestyle-related arthritis, greater utilization of uric acid-lowering therapies, the broadening scope of chronic gout management, heightened awareness regarding early diagnosis, and better long-term monitoring of the disease.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=95647685&type=smp&name=Gout%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Gout Therapeutics Market Growth Drivers: What’s Behind The Acceleration?

The increasing prevalence of gout is anticipated to drive the expansion of the gout therapeutics market in the future. Gout is defined as an inflammatory form of arthritis characterized by joint pain and swelling. This increase in gout cases largely stems from obesity and metabolic syndrome, conditions that elevate uric acid concentrations in the bloodstream, resulting in the crystallization of urate within joints. Therapies for gout effectively mitigate its incidence and severity through mechanisms such as reducing uric acid levels, controlling inflammation, and averting acute attacks. For example, a publication in June 2025, cited by PubMed Central, a U.S.-based platform for biomedical and life sciences journals, indicated that by 2050, age-standardized rates of gout incidence and prevalence are forecast to rise even more, signifying a growing global burden of the disease. Additionally, in June 2024, data from The National Library of Medicine (NLM), a US-based largest biomedical library, revealed that in 2023, the coexistence of gout and chronic kidney disease (CKD) affected 7.9 million individuals in the USA, a figure expected to climb by 29% to 9.6 million by 2035 under a baseline projection. Consequently, the escalating incidence of gout is acting as a key driver for the expansion of the gout therapeutics market.

Gout Therapeutics Market Segment Landscape And Growth Outlook

The gout therapeutics market covered in this report is segmented –

1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics

2) By Treatment: Xanthine Oxidase Inhibitor, Uricosuria Medication

3) By Disease Condition: Acute, Chronic

4) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, Selective COX-2 Inhibitors

2) By Corticosteroid: Oral Corticosteroids, Injectable Corticosteroids

3) By Diuretics: Thiazide Diuretics, Loop Diuretics

Gout Therapeutics Market Trends Redefining Industry Growth

Leading companies in the gout therapeutics market are developing innovative products, such as urate transporters, which facilitate the reabsorption of uric acid from the urine back into the blood. A urate transporter is a protein that assists in moving uric acid (urate) across cell membranes in the kidneys or intestines, thereby regulating blood uric acid levels. For instance, in July 2025, Eisai Co. Ltd., a Japan-based pharmaceutical company, introduced URECE (dotinurad), a selective urate transporter 1 (URAT1) inhibitor, now part of Eisai’s global specialty care portfolio. URECE is utilized for treating hyperuricemia associated with gout, effectively lowering serum uric acid levels by enhancing its excretion through the kidneys. Additionally, it presents a favorable safety profile with minimal off-target effects and demonstrated efficacy in patients with mild-to-moderate renal impairment, making it appropriate for a diverse group of gout patients.

Gout Therapeutics Market Competitive Landscape: Who Leads The Industry?

Major companies operating in the gout therapeutics market are Takeda Pharmaceutical Company Ltd, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, Teijin Pharma Ltd, Zydus Group, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Limited, Ironwood Pharmaceuticals Inc, Pharvaris NV, Selecta Biosciences Inc, Dyve Biosciences Inc, Arthrosi Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC

View The Full Gout Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Gout Therapeutics Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the gout therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model